New combo pill aims to tame stubborn high blood pressure

NCT ID NCT06671392

Completed Disease control Sponsor: Daewoong Pharmaceutical Co. LTD. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 3 trial tested whether adding a third drug (DWC202314) to a two-drug combination pill works better for people with essential hypertension that isn't controlled by the two-drug pill alone. 198 participants took either the two-drug or three-drug combination once daily. The study measured changes in sitting systolic blood pressure over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: combination pill (DWC202405/DWC202313 plus DWC202314)
What this could lead to: If successful, this could offer a more effective once-daily pill for people whose high blood pressure is not well controlled with current treatment.
What could go wrong: This is a completed Phase 3 trial, but results are not yet published. The new combination may not prove significantly better than existing options, and side effects are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESSENTIAL HYPERTENSION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

essential hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESSENTIAL HYPERTENSION

Contacts and locations

Locations

Korea University ANAM Hospital

Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.